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Practice Points:  21 
 Oxygen cost of walking is significantly higher in people with Multiple Sclerosis 22 
compared to healthy controls.  23 
 Evidence from a small number of studies highlights that oxygen cost of walking may be 24 
positively correlated with fatigue suggesting that higher levels of fatigue are associated 25 
with greater energy expenditure while walking.  26 
 Future studies should determine whether interventions (e.g. exercise) which reduce 27 
energy cost of walking also positively influences fatigue. 28 




Background: This systematic review and meta-analysis aimed to: 1) compare the oxygen 31 
cost of walking in people with MS to healthy controls; 2) assess the relationship between 32 
oxygen cost of walking and fatigue in people with MS. 33 
Methods: Four databases (CINAHL, MEDLINE, ProQuest, Web of Science) were searched 34 
up to September 2020. Studies were included if they recruited adults with MS and either 35 
compared oxygen cost of walking to a healthy control population or determined the 36 
relationship between oxygen cost of walking and fatigue. Meta-analysis of the standardised 37 
mean difference in oxygen cost of walking between people with MS and healthy controls was 38 
performed.  39 
Results: 9 studies were included in this review of which 7 compared oxygen cost of walking 40 
in people with MS (n=176) to healthy controls (n=142), and 4 investigated the relationship 41 
between oxygen cost of walking and fatigue. Meta-analysis revealed that people with MS 42 
(with predominately mild-moderate disability) had a significantly higher oxygen cost of 43 
walking compared to health controls (SMD = 2.21; 95% CI = 0.88, 3.54; p = 0.001).  In 44 
addition, 3 studies found a significant yet weak positive association between oxygen cost of 45 
walking and fatigue.  46 
Conclusions: People with MS expend greater amounts of energy when walking compared to 47 
healthy controls. This increase in energy expenditure may contribute to the development of 48 
fatigue, as a small number found that higher oxygen costs of walking were associated with 49 
greater levels of fatigue. Therefore, future studies should investigate whether reducing energy 50 
expenditure during movement improves fatigue.  51 




Multiple Sclerosis (MS) is a chronic demyelinating disease of the central nervous system 54 
which manifests in impaired nerve conduction and dysfunction of neural pathways.1 The 55 
clinical manifestation of MS is heterogeneous and dependent upon the location of 56 
demyelination; although, lesions typically impact motor, sensory, visual, and cerebellar 57 
function.2 Consequently, walking impairments are a common feature of MS and are reported 58 
in up to 68% of the population.3 Reductions in walking speed and endurance are often 59 
demonstrated by people with MS,4-6 alongside altered gait kinematics such as lower cadence, 60 
shortened stride length, and increase time spent in double-limb support.7,8 These alterations in 61 
gait performance are suggested to reduce the efficiency of movement resulting in increased 62 
energy expenditure.9  63 
 64 
Energy expenditure while walking is commonly quantified by measuring the changes in 65 
metabolic rate associated with the movement – i.e. the oxygen cost of walking. The oxygen 66 
cost of walking is defined as the volume of oxygen consumed per kilogram of body weight 67 
over the distance travelled, and reflects the total energy required for muscle activation and the 68 
maintenance of balance and posture in order to sustain locomotion.9 Increased oxygen costs 69 
of walking can be used as a physiological marker of gait impairment to indicate either greater 70 
levels of energy expenditure used to travel the same distance or a reduction in the distance 71 
travelled for the same level of energy expenditure. In people with MS, disability10-12 and 72 
slower walking speeds12,13 are positively associated with oxygen cost of walking indicating 73 
that people with higher levels of gait impairments expend greater amounts of energy while 74 
walking. However, despite the prevalence of gait impairments, it is currently unclear whether 75 
energy expenditure during functional tasks such as walking is indeed higher in MS 76 
populations.  77 
 78 
If oxygen cost of walking is found to be elevated in people with MS, then a consequence of 79 
this may be the development of fatigue – particularly with the progression of disability. 80 
Fatigue is one of the most common symptoms of MS which is reported by over 70% of the 81 
population,14-16 and can be defined as “a subjective lack of physical and/or mental energy that 82 
is perceived by the individual or caregiver to interfere with usual and desired activities”.17 83 
Although the exact causes of MS-related fatigue are unclear it has been proposed that 84 
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expending greater amounts of energy during activities of daily living may increase the 85 
subjective perception of effort and thus lead to increased fatigue.18 Therefore, reducing the 86 
energy cost of movement could present a potential therapeutic target for interventions aimed 87 
at improving fatigue. However, despite the potential role of energy expenditure in the 88 
development of fatigue, no systematic review has yet evaluated the available evidence to 89 
determine the association between fatigue and oxygen cost of walking in MS populations; 90 
consequently, the relationship between energy expenditure and fatigue remains unclear. 91 
 92 
Accordingly, the aims of this review are to: 1) compare the oxygen cost of walking in people 93 
with MS to healthy controls; 2) assess the relationship between oxygen cost of walking and 94 
fatigue in people with MS.  95 
 96 
Methods 97 
Eligibility criteria  98 
Observational studies (with either a cross-sectional or prospective design) or randomised 99 
controlled trials which recruited adults with MS were included in this review if they directly 100 
measured oxygen cost of walking using a standardised testing protocol and met one of the 101 
following criteria: 1) compared the oxygen cost of walking in people with MS to healthy 102 
controls; 2) reported the association between oxygen cost of walking and fatigue (using any 103 
self-reported outcome measure) in people with MS. Studies with a longitudinal design were 104 
only included if mean difference and/or associations between oxygen cost of walking and 105 
fatigue was reported using baseline values. Only full-text articles published in English were 106 
included in this review and when the results of the same study were reported in multiple 107 
articles, only the original article was included in this review. Grey literature and conference 108 
abstracts were excluded.  109 
 110 
Search strategy  111 
A review protocol was registered with PROSPERO in September 2020 (CRD42020207500), 112 
and searches were conducted of the following databases from inception: CINAHL (via 113 
EBSCOhost), MEDLINE (via Ovid), ProQuest (Health & Medical Collection, Nursing & 114 
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Allied Health Database, Sports Medicine & Education Index) and Web of Science Core 115 
Collections. The following search strategy comprised of keywords was used in each database: 116 
("Multiple Sclerosis") AND ("oxygen cost" OR "oxygen consumption" OR "oxygen uptake" 117 
OR "VO2" OR "energy cost" OR "energy expenditure" OR "energy efficiency" OR "energy 118 
requirement" OR "metabolic cost") AND ("walking" OR "gait" "locomotion" OR "activit* of 119 
daily living" OR "functional task*" OR "mobility task*"). Reference lists of included articles 120 
were also hand searched to identify additional articles.  121 
 122 
Study selection  123 
Study selection was conducted using Covidence systematic review software. After removing 124 
duplicates, the title and abstracts of all articles were screened against the eligibility criteria by 125 
one reviewer. Subsequently, two reviewers independently screened full texts of the remaining 126 
articles for eligibility. Disagreements were resolved through consensus in consultation with a 127 
third reviewer if required.  128 
 129 
Quality assessment  130 
Methodological quality of included studies was assessed by two reviewers using the Joanna 131 
Briggs Institute Critical Appraisal Checklist for Analytical Cross-Sectional Studies. Quality 132 
assessment was completed independently by each reviewer, and any discrepancies between 133 
reviewers were resolved through consensus in consultation with a third reviewer if required. 134 
Prior to completing the quality assessment, a pilot assessment was conducted where each 135 
reviewer read and independently scored an article to ensure consistency in assessment. No 136 
studies were excluded based on the result of the quality assessment. 137 
 138 
Data extraction  139 
Data extraction was completed independently by one reviewer using a standardised data 140 
extraction form. Data extracted from studies included: study details (author, year of 141 
publication, study design), participant demographics (total number, age, gender, disability, 142 
MS-type), methods of measuring oxygen cost of walking (test duration, over-ground vs. 143 
treadmill walking, walking speed, measurement equipment, calculation of oxygen cost, use of 144 
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walking aids), and the outcome measures used to assess fatigue (if applicable). For studies 145 
which compared oxygen cost of walking in people with MS to healthy controls, the mean 146 
values for oxygen cost of walking in the MS and control groups were extracted along with the 147 
mean difference and associated p-value. Additionally, for studies which report the association 148 
between oxygen cost of walking and fatigue, the value of the correlation coefficient was 149 
extracted.  150 
 151 
Data synthesis  152 
Narrative synthesis  153 
The results of all included studies were analysed through narrative synthesis. Firstly the mean 154 
difference in oxygen cost of walking reported by individual studies was classified by 155 
direction and statistical significance (p<0.05) to determine whether oxygen cost of walking is 156 
significantly higher in the control or MS groups, or whether no significant difference was 157 
found. These findings were then compared across studies to determine whether a consistent 158 
difference was reported. Studies were also categorised according to the method used to 159 
measure oxygen cost (e.g. treadmill vs. over-ground walking, fixed vs. self-selected walking 160 
speed), and values for mean difference were compared within groups to determine the 161 
consistency of the results. Lastly, the association between fatigue and oxygen cost of walking 162 
was compared across studies, and findings were classified according to the direction and 163 
statistical significance of the reported correlation coefficients – i.e. a significant positive 164 
correlation, significant negative correlation, or no significant association. 165 
Meta-analysis  166 
Meta-analysis of the mean difference in oxygen cost of walking between people with MS and 167 
healthy controls was performed if oxygen cost of walking was assessed using the same units 168 
of measurement (i.e. mL/kg/m) in two or more studies. When data were reported for multiple 169 
walking speeds, only the self-selected/comfortable walking speed was included in the meta-170 
analysis – studies which did not identify a self-selected/comfortable walking speed were 171 
excluded. Due to differences in methods of calculating oxygen cost (e.g. net oxygen 172 
consumption vs. total oxygen consumption), standardised mean differences were calculated 173 
using the mean and standard deviation extracted from each study. Summary estimates 174 
including 95% CI were then reported for each individual study and overall findings using 175 
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Revman software v5.3 (2019, Cochrane Collaboration, UK). Heterogeneity in results across 176 
studies was assessed using I2, and a random effects model was used due to evidence of 177 
significant heterogeneity (I2 >40%). To account for differences in methods used between 178 
studies to measure oxygen cost, a sensitivity analysis was performed to compare the results of 179 
studies that used fixed vs. self-selected walking speeds. 180 
 181 
Results  182 
Search results 183 
The search strategy identified 282 articles and, after removing 120 duplicates, the title and 184 
abstracts of 162 articles were screened against the eligibility criteria. Of these articles, 139 185 
were excluded, and the full-texts of the remaining 23 articles were screened. 14 articles were 186 
excluded after full-text screening as six articles did not include a control group or fatigue 187 
outcome measure, five did not include a measure of oxygen cost of walking, one did not 188 
report the difference in oxygen cost of walking between people with MS and healthy 189 
controls, one did not report the relationship between oxygen cost of walking and fatigue, and 190 
the results of one study were reported in another article. Therefore, nine articles were 191 
included in this review (Figure S1).10,12,13,19-24 Of the included articles, all reported the results 192 
of cross-sectional studies with seven examining the difference in oxygen cost of walking in 193 
people with MS compared to healthy controls (Table S1),10,19-24 and four examining the 194 
association between oxygen cost of walking and fatigue in people with MS (including two of 195 
the studies that examined the difference in oxygen cost of walking in people with MS 196 
compared to healthy controls;23,24 Table S2).12,13,23,24  197 
 198 
Participants 199 
In total, 302 people with MS were included in the nine articles in this review with sample size 200 
ranging from 10-82. Participants were mostly female (77%) with a relapsing-remitting 201 
diagnosis of MS (79%), and the mean age of participants ranged from 39.0-54.1 years. 202 
Disability was measured using the Expanded Disability Status Scale (EDSS) in two 203 
articles,21,23 and the Patient Determined Disease Steps (PDDS) in four articles,10,12,13,22 with 204 




Oxygen cost of walking measurement  207 
Walking protocol 208 
Of the studies included in this review, five used a treadmill walking protocol when measuring 209 
oxygen cost of walking10,13,19,22,23 and four used an over-ground walking protocol.12,20,21,24 210 
The duration of walking trials was six minutes in the majority of studies (n=6),10,12,13,19,21,22 211 
with remaining studies using a five minute protocol (n=3).20,23,24 Of the studies that used a 212 
treadmill protocol, participants walked at a constant speed throughout the trial with the 213 
exception of the study by Olgiati et al.19 where participants walked at 1.5 km/h for three 214 
minutes followed by 2.0 km/h for another three minutes. Three studies included multiple 215 
treadmill walking trials at various speeds, with Chung et al.23 and Motl et al.10 including three 216 
different walking speeds, and Sandroff et al.22 including five different walking speeds. All 217 
over-ground walking trials were performed at the participant’s self-selected walking speed 218 
(range of means = 0.43-1.33 m/s). All of the participants in the studies by Paul et al.20 and 219 
Devasahayam et al.24 used walking aids, whereas no walking aids were used by participants 220 
in the study by Franceschini et al.21  221 
 222 
Calculation of oxygen cost 223 
All studies measured oxygen consumption while walking using metabolic measurement 224 
systems with the exception of Olgiati et al.19 which used rubber balloons to collect expired 225 
gas that was then analysed using a dry gas meter. The majority of studies used the mean 226 
steady-state oxygen consumption when calculating oxygen cost of walking – this was defined 227 
as the mean oxygen consumption during the final two minutes,23,24 final three 228 
minutes,10,12,13,22 or 4th minute (out of five) of the walking trial.20 Only two studies used the 229 
mean oxygen consumption during the full duration of the walking trial when calculating 230 
oxygen cost.19,21 The method used to calculate oxygen cost of walking varied between 231 
studies, as four studies calculated oxygen cost as net oxygen consumption (i.e. oxygen 232 
consumption while walking – oxygen consumption at rest) divided by walking speed,12,13,19,23 233 
whereas four studies calculated oxygen cost as gross oxygen consumption (i.e. oxygen 234 




Study quality  237 
The number of items that were adequately addressed on the Joanna Briggs Institute Critical 238 
Appraisal Checklist for Analytical Cross-Sectional Studies ranged from 6-8 (Table S3). Of 239 
the studies that included a control group, all adjusted for confounding variables by recruiting 240 
age and sex matched healthy controls. In addition, all studies used valid and reliable methods 241 
to assess oxygen cost of walking. However, three studies did not include a clear description 242 
of the criteria used to confirm diagnosis of MS.19,20,23 Furthermore, one study did not 243 
adequately report the demographic characteristics of the study population.19 244 
 245 
Oxygen cost of walking in Multiple Sclerosis vs. healthy controls  246 
Oxygen cost of walking was found to be significantly higher in people with MS compared to 247 
healthy controls by all studies included in this review. Of the studies that measured oxygen 248 
cost of walking at self-selected walking speeds, mean values ranged from 0.10-0.60 ml/kg/m 249 
in people with MS and 0.06-0.22 ml/kg/m in healthy controls.20,21,23,24 The studies which 250 
reported the largest difference in oxygen cost of walking between MS and healthy controls at 251 
self-selected speeds (-0.280 ml/kg/m; -0.380 ml/kg/m) also reported the highest values for 252 
oxygen cost of walking in those with MS (0.46 ml/kg/m; 0.60 ml/kg/m);20,24 both studies 253 
used an over-ground walking protocol and predominantly included people with progressive 254 
forms of MS (83-93%) – all of whom required walking aids. Conversely, the study which 255 
reported the lowest value for oxygen cost of walking (0.10 ml/kg/m) used a treadmill 256 
protocol where participants did not use any walking aids.23 Of the studies which measured 257 
oxygen cost of walking across various treadmill speeds, a consistent significant difference 258 
between people with MS and healthy controls was found at speeds of 54 m/min to 94 259 
m/min,10,22 but not at 107 m/min.22 Similarly, using different walking speeds, Chung et al. 260 
only found a significant difference in the oxygen cost of walking between people with MS 261 
and healthy controls at slower gait speeds (mean difference: 0.6 m/s = -0.110 ml/kg/m, p ≤ 262 
0.001; 1.4 m/s = -0.010 ml/kg/m, p > 0.05).23  263 
 264 
When the standardized mean difference was pooled in a meta-analysis (Figure 1), oxygen 265 
cost of walking was found to be significantly greater in people with mild to moderate MS 266 
compared to healthy controls (SMD (95% CI) = 2.21 (0.88, 3.54), p = 0.001). However, there 267 
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was evidence of significant heterogeneity as the magnitude of difference varied across studies 268 
within the meta-analysis (I2 = 91%, p < 0.001). In line with the methods of this review, two 269 
studies were excluded from this meta-analysis as these studies measured oxygen cost across 270 
various walking speeds and did not identify a self-selected/comfortable walking speed.10,22 271 
When only the results from studies that measured oxygen cost of walking at self-selected 272 
walking speeds were pooled,20,21,23,24 a smaller, more consistent effect was found (SMD (95% 273 
CI) = 1.32 (0.73, 1.90), p < 0.001). Similarly, a smaller yet significant effect was found in 274 
studies that measured oxygen cost of walking at variable walking speeds (SMD (95% CI) = 275 
1.53 (0.86, 2.20), p < 0.001)20,21,24 compared to fixed speeds (SMD (95% CI) = 3.29 (-1.96, 276 
8.55), p > 0.05).19,23 However, due to small number of studies with variable sample sizes and 277 
population demographics, it is unclear whether the differences in measurement methods 278 
indeed account for the difference in results.  279 
 280 
Figure 1 near here 281 
 282 
Relationship between oxygen cost of walking and fatigue 283 
Across the studies which investigated the association between oxygen cost of walking and 284 
fatigue, three studies measured fatigue using outcomes which required participants to recall 285 
symptoms over a period of time (e.g. Fatigue Severity Scale, Modified Fatigue Impact 286 
Scale),12,13,24 whereas two studies measured fatigue immediately following completion of a 287 
walking test.23,24 Of these studies, two reported a significant weak relationship (r ≤ 0.3, p ≤ 288 
0.05) between oxygen cost of walking and Fatigue Severity Scale scores, suggesting that 289 
higher oxygen costs of walking may be associated with greater levels of fatigue.12,13 While, 290 
the study by Devasahayam et al.24 found no significant association between oxygen cost of 291 
walking and fatigue (measured using the Fatigue Severity Scale and Modified Fatigue Impact 292 
Scale), this study had a considerably smaller sample size compared to those which found a 293 
significant association (1424 vs. 44-8212,13). Of the studies which measured fatigue 294 
immediately following completion of a walking task,23,24 only one found fatigue to be 295 
moderately associated with oxygen cost of walking – this study included people with higher 296 





The evidence from the nine articles included in this systematic review and meta-analysis 300 
highlights that people with MS expend greater amounts of energy during walking, as oxygen 301 
cost of walking was found to be significantly higher in people with MS compared to healthy 302 
controls. In addition, evidence from a small number of studies suggests that higher oxygen 303 
costs of walking may be weakly associated with greater levels of fatigue, indicating a 304 
potential role of energy expenditure in the development of fatigue symptoms. Therefore, 305 
reducing energy expenditure during functional tasks such as walking could present a potential 306 
therapeutic target for interventions aimed at improving fatigue in people with MS. However, 307 
the relationship between oxygen cost of walking and fatigue remains unclear due to 308 
inconsistent evidence from a small number of studies that used various different fatigue 309 
outcome measures likely measuring different aspects of fatigue. Accordingly further research 310 
is required to determine the impact of increased energy cost of walking on the clinical 311 
features of MS such as fatigue.  312 
 313 
Despite the prevalence of walking impairments in people with MS,3 only seven studies were 314 
found that compared oxygen cost of walking in people with MS to healthy control 315 
populations. However, the evidence from this small number of studies consistently 316 
demonstrated higher oxygen costs in people with MS. At self-selected walking speeds 317 
(ranging between 0.43-1.33 m/s), people with MS were found to consume 30%-170% more 318 
oxygen per meter walked compared to healthy controls; this approximately equates to an 319 
increase of 0.011-0.108 METs/m. Therefore, the evidence presented in this review confirms 320 
the hypothesis that people with MS with mild to moderate disability expend greater amounts 321 
of energy while walking; this finding is similar to evidence from other neurological diseases 322 
including Stroke, Cerebral Palsy, and Parkinson’s disease.25-27  323 
 324 
While oxygen cost of walking was found to be consistently higher in people with MS, the 325 
mean value for oxygen cost and the magnitude of difference compared to healthy controls 326 
varied across the studies included in this review depending on the population recruited and 327 
walking protocol used. For instance, studies which recruited predominantly people with 328 
progressive MS reported higher oxygen costs of walking, and thus a greater difference 329 
compared to healthy controls.20,24  As people with progressive MS generally present with 330 
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more severe mobility impairments,28 this finding is in line with previous evidence which 331 
demonstrates that oxygen cost of walking is higher in people with greater levels of 332 
disability.10,12 In addition, differences in walking test protocols may also account for the 333 
variation in oxygen cost, as when walking at matched speeds, oxygen cost of walking was 334 
only found to be higher in people with MS at slower walking speeds. Although there were 335 
differences in oxygen cost of walking between studies that used treadmill or over-ground 336 
walking protocols, it is unclear whether these differences can be attributed to changes in 337 
movement patterns while treadmill walking29,30 or the use of walking aids in over-ground 338 
tests.11,12  339 
 340 
The mechanisms through which the oxygen cost of functional tasks such as walking are 341 
increased in people with MS are not yet determined but likely include factors related to 342 
disability, lower-limb spasticity, deconditioning, and walking impairments. As previously 343 
stated, studies included in this review reported higher oxygen costs of walking in populations 344 
with greater levels of disability. Furthermore, previous studies report that disability and 345 
oxygen cost of walking are positively associated, further indicating people with higher levels 346 
of disability expend greater amounts of energy during walking.10,12 While the causal 347 
influence of this relationship is unclear, it is likely that disability directly influences energy 348 
expenditure due to the association between oxygen cost and gait and balance 349 
impairments.12,13,31,32 Additionally, people with MS have a reduction in the number and size 350 
of fatigue resistant type 1 muscle fibres along with a decrease in muscle oxidative capacity;33-351 
36 consequently, these changes in muscle structure and function may also increase oxygen 352 
consumption during functional tasks due to changes in mitochondrial function and the ability 353 
to meet the energy requirements of the task. However, no study has yet determined whether 354 
these factors indeed contribute to the greater energy expenditure observed in MS populations. 355 
Therefore, further research is required to investigate the mechanisms that cause increased 356 
oxygen cost of walking in order to identify effective interventions to reduce energy 357 
expenditure.  358 
 359 
The evidence presented in this systematic review also highlights the possible role of 360 
deconditioning in the development of fatigue due the positive association found between 361 
oxygen cost of walking and fatigue. People with MS are generally found to be deconditioned 362 
14 
 
as previous systematic reviews have reported that both cardiorespiratory fitness and muscle 363 
strength are lower in MS populations compared to healthy controls.37,38 Furthermore, higher 364 
levels of deconditioning are associated with greater energy costs during activities of daily 365 
living – particularly during walking.39 Therefore, greater oxygen cost of walking as a result of 366 
deconditioning may increase the perception of effort during functional tasks, thus leading to 367 
fatigue. However, due to the small number of studies included in this review, differences in 368 
fatigue outcome measures used across studies, and cross-sectional nature of the evidence, the 369 
presence and magnitude of association and direction of causality between oxygen cost of 370 
walking and fatigue is unclear. Accordingly, further studies are required to evaluate the 371 
association between oxygen cost of walking and fatigue to determine the relative roles of 372 
energy expenditure and deconditioning in the development of fatigue. Furthermore, future 373 
studies should also evaluate whether reversing the effects of deconditioning and improving 374 
walking performance in people with MS positively affects energy expenditure and fatigue.   375 
 376 
If oxygen cost of walking is indeed associated with fatigue in people with MS, then 377 
interventions such as exercise which aim improve cardiorespiratory fitness have the potential 378 
to reduce fatigue. For example, as higher levels of aerobic capacity are associated with lower 379 
energy expenditure during functional tasks,39 then reducing relative energy expenditure (i.e. 380 
expending energy at a lower percentage of maximal energy expenditure) through sufficiently 381 
intense aerobic exercise training may also lead to improvements in fatigue.18 However, it is 382 
important to consider the increased energy demand in people with MS when prescribing 383 
exercise and modify the type and intensity of exercise prescription in line with current 384 
exercise recommendations.40  385 
 386 
Limitations 387 
There are several important limitations to consider when interpreting the findings of this 388 
review. Firstly, the methods used to measure oxygen cost of walking were inconsistent across 389 
the included studies. While some studies controlled for resting metabolic rate by calculating 390 
net oxygen consumption, other studies used gross oxygen consumption values to calculate 391 
oxygen cost of walking. Additionally, while most studies used steady-state oxygen 392 
consumption in determining oxygen cost of walking, the criteria used to define steady-state 393 
varied between studies, and it was unclear whether participants had indeed achieved steady-394 
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state oxygen consumption in each study. As a result of the variance in measurement methods, 395 
standardised mean difference in oxygen costs of walking were used in this meta-analysis 396 
which limits the interpretability of the results. Accordingly, standardised methods of 397 
measuring oxygen cost should be defined for future research. Secondly, the findings of this 398 
review are based on a small number of studies – most of which included participants with 399 
low-moderate levels of disability. Therefore, further research is required to measure oxygen 400 
cost of walking in MS populations with more severe levels of disability and gait impairment. 401 
Lastly, the findings of this review are limited by the cross-sectional design of the included 402 
studies, meaning it was not possible to determine the direction of causality between oxygen 403 
cost of walking and fatigue; consequently, it is unclear whether changes in fatigue account 404 




This systematic review and meta-analysis found that oxygen cost of walking was higher in 409 
people with MS who have mild to moderate disability compared to healthy controls, which 410 
highlights that people with MS expend greater amounts of energy during walking. In 411 
addition, a small number of studies found that a higher oxygen cost of walking was 412 
associated with greater levels fatigue. Therefore, these findings suggest that rehabilitation 413 
interventions which aim to reduce oxygen cost of walking may have a positive impact on 414 
fatigue symptoms. However, further research is needed to investigate the impact of increased 415 
energy cost of walking on the clinical features of MS such as fatigue in order to determine 416 
whether reducing energy expenditure improves overall fatigue symptoms.  417 
 418 
Conflicts of interest: None 419 
Funding: The first author is funded by a Glasgow Caledonian University PhD Studentship 420 
 421 




1. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. The 424 
Lancet. 2018;391(10130):1622-1636. 425 
2. Compston A, Coles A. Multiple sclerosis. The Lancet. 2008;372(9648):1502-1517. 426 
3. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The multiple sclerosis impact 427 
scale (MSIS-29): A new patient-based outcome measure. Brain. 2001;124(Pt 5):962-973. 428 
4. Goldman MD, Marrie RA, Cohen JA. Evaluation of the six-minute walk in multiple 429 
sclerosis subjects and healthy controls. Mult Scler. 2008;14(3):383-390. 430 
5. Kalron A, Achiron A, Dvir Z. Muscular and gait abnormalities in persons with early onset 431 
multiple sclerosis. J Neurol Phys Ther. 2011;35(4):164-169. 432 
6. Burschka JM, Keune PM, Menge U, Hofstadt-van Oy U, Oschmann P, Hoos O. An 433 
exploration of impaired walking dynamics and fatigue in multiple sclerosis. BMC Neurol. 434 
2012;12:1-8. 435 
7. Thoumie P, Lamotte D, Cantalloube S, Faucher M, Amarenco G. Motor determinants of 436 
gait in 100 ambulatory patients with multiple sclerosis. Mult Scler. 2005;11(4):485-491. 437 
8. Martin CL, Phillips BA, Kilpatrick TJ, et al. Gait and balance impairment in early multiple 438 
sclerosis in the absence of clinical disability. Mult Scler. 2006;12(5):620-628. 439 
9. Waters RL, Mulroy S. The energy expenditure of normal and pathologic gait. Gait 440 
Posture. 1999;9(3):207-231. 441 
10. Motl RW, Suh Y, Dlugonski D, et al. Oxygen cost of treadmill and over-ground walking 442 
in mildly disabled persons with multiple sclerosis. Neurol Sci. 2011;32(2):255-262. 443 
11. Coote S, O'Dwyer C. Energy expenditure during everyday activities--a study comparing 444 
people with varying mobility limitations due to multiple sclerosis and healthy controls. 445 
Disabil Rehabil. 2014;36(24):2059-2064. 446 
12. Sandroff BM, Klaren RE, Pilutti LA, Motl RW. Oxygen cost of walking in persons with 447 
multiple sclerosis: Disability matters, but why? Multiple Sclerosis International. 448 
2014;2014:1-7. 449 
13. Motl RW, Sandroff BM, Suh Y, Sosnoff JJ. Energy cost of walking and its association 450 
with gait parameters, daily activity, and fatigue in persons with mild multiple sclerosis. 451 
Neurorehabilitation & Neural Repair. 2012;26(8):1015-1021. 452 
17 
 
14. Lerdal A, Celius EG, Krupp L, Dahl AA. A prospective study of patterns of fatigue in 453 
multiple sclerosis. Eur J Neurol. 2007;14(12):1338-1343. 454 
15. Hadjimichael O, Vollmer T, Oleen-Burkey M, North American Research Committee on 455 
Multiple Sclerosis. Fatigue characteristics in multiple sclerosis: The north american research 456 
committee on multiple sclerosis (NARCOMS) survey. Health Qual Life Outcomes. 2008;6:1-457 
11. 458 
16. Rooney S, Wood L, Moffat F, Paul L. Prevalence of fatigue and its association with 459 
clinical features in progressive and non-progressive forms of multiple sclerosis. Multiple 460 
Sclerosis and Related Disorders. 2019;28:276-282.  461 
17. Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and multiple 462 
sclerosis: Evidence-based management strategies for fatigue in multiple sclerosis. 463 
Washington, DC: Paralyzed Veterans of America; 1998. 464 
18. Langeskov-Christensen M, Bisson EJ, Finlayson ML, Dalgas U. Potential 465 
pathophysiological pathways that can explain the positive effects of exercise on fatigue in 466 
multiple sclerosis: A scoping review. J Neurol Sci. 2017;373:307-320. 467 
19. Olgiati R, Burgunder JM, Mumenthaler M. Increased energy cost of walking in multiple 468 
sclerosis: Effect of spasticity, ataxia, and weakness. Archives of Physical Medicine & 469 
Rehabilitation. 1988;69(10):846-849. 470 
20. Paul L, Rafferty D, Young S, Miller L, Mattison P, McFadyen A. The effect of functional 471 
electrical stimulation on the physiological cost of gait in people with multiple sclerosis. Mult 472 
Scler. 2008;14(7):954-961. 473 
21. Franceschini M, Rampello A, Bovolenta F, Aiello M, Tzani P, Chetta A. Cost of walking, 474 
exertional dyspnoea and fatigue in individuals with multiple sclerosis not requiring assistive 475 
devices. J Rehabil Med. 2010;42(8):719-723. 476 
22. Sandroff BM, Motl RW, Suh Y. Accelerometer output and its association with energy 477 
expenditure in persons with multiple sclerosis. Journal of Rehabilitation Research and 478 
Development. 2012;49(3):467-75. 479 
23. Chung LH, Angelo J, van Emmerik REA, Kent JA. Energy cost of walking, symptomatic 480 
fatigue and perceived exertion in persons with multiple sclerosis. Gait Posture. 2016;48:215-481 
219. 482 
24. Devasahayam AJ, Kelly LP, Wallack EM, Ploughman M. Oxygen cost during mobility 483 
tasks and its relationship to fatigue in progressive multiple sclerosis. Archives of Physical 484 
Medicine & Rehabilitation. 2019;100(11):2079-2088. 485 
18 
 
25. Johnston TE, Moore SE, Quinn LT, Smith BT. Energy cost of walking in children with 486 
cerebral palsy: Relation to the gross motor function classification system. Dev Med Child 487 
Neurol. 2004;46(1):34-38. 488 
26. Christiansen CL, Schenkman ML, McFann K, Wolfe P, Kohrt WM. Walking economy in 489 
people with parkinson's disease. Mov Disord. 2009;24(10):1481-1487. 490 
27. Kramer S, Johnson L, Bernhardt J, Cumming T. Energy expenditure and cost during 491 
walking after stroke: A systematic review. Arch Phys Med Rehabil. 2016;97(4):619-632. 492 
28. Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA. Age and disability 493 
accumulation in multiple sclerosis. Neurology. 2011;77(13):1246-1252. 494 
29. Alton F, Baldey L, Caplan S, Morrissey MC. A kinematic comparison of overground and 495 
treadmill walking. Clin Biomech. 1998;13(6):434-440. 496 
30. Lee SJ, Hidler J. Biomechanics of overground vs. treadmill walking in healthy 497 
individuals. J Appl Physiol (1985). 2008;104(3):747-755. 498 
31. Jeng B, Sandroff BM, Motl RW. Energetic cost of walking and spasticity in persons with 499 
multiple sclerosis with moderate disability. NeuroRehabilitation. 2018;43(4):483-489. 500 
32. Kalron A, Frid L, Menascu S, Givon U. The association between gait variability with the 501 
energy cost of walking depends on the fall status in people with multiple sclerosis without 502 
mobility aids. Gait Posture. 2019;74:231-235. 503 
33. Kent-Braun JA, Sharma KR, Miller RG, Weiner MW. Postexercise phosphocreatine 504 
resynthesis is slowed in multiple sclerosis. Muscle Nerve. 1994;17(8):835-841. 505 
34. Kent-Braun JA, Ng AV, Castro M, et al. Strength, skeletal muscle composition, and 506 
enzyme activity in multiple sclerosis. J Appl Physiol (1985). 1997;83(6):1998-2004. 507 
35. Wens I, Dalgas U, Vandenabeele F, Krekels M, Grevendonk L, Eijnde BO. Multiple 508 
sclerosis affects skeletal muscle characteristics. PLoS One. 2014;9(9):1-5. 509 
36. Harp MA, McCully KK, Moldavskiy M, Backus D. Skeletal muscle mitochondrial 510 
capacity in people with multiple sclerosis. Mult Scler J Exp Transl Clin. 2016;2:1-7. 511 
37. Langeskov-Christensen M, Heine M, Kwakkel G, Dalgas U. Aerobic capacity in persons 512 
with multiple sclerosis: A systematic review and meta-analysis. Sports Med. 2015;45(6):905-513 
923. 514 
38. Jorgensen M, Dalgas U, Wens I, Hvid LG. Muscle strength and power in persons with 515 
multiple sclerosis - A systematic review and meta-analysis. J Neurol Sci. 2017;376:225-241. 516 
19 
 
39. Jeng B, Sandroff BM, Motl RW. Energetic cost of walking and its physiological 517 
correlates in persons with multiple sclerosis who have moderate mobility disability. Archives 518 
of Physical Medicine and Rehabilitation. 2018;99(10):2038-2044.   519 
40. Kalb R, Brown TR, Coote S, Costello K, Dalgas U, Garmon E, et al. Exercise and 520 
lifestyle physical activity recommendations for people with multiple sclerosis throughout the 521 
disease course. Multiple Sclerosis. 2020;26(12), 1459-1469. 522 
  523 
 524 




Figure 1 Meta-analysis comparing the standardised mean difference of oxygen cost of walking in people with Multiple Sclerosis to healthy controls   527 
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Table S1 Characteristics and main findings of the studies which investigated the difference in oxygen cost of walking between people with MS 












JBI = 6 
N = 33 (F/M NR) 
MS type: NR  
EDSS: NR  
Age, years (mean ± SD) 
= 41.0 ± 1.7 
Weight, kg (mean ± 
SD) = 67.0 ± 2.1 
N = 12 (6 F/6 M) 
Age, years (mean ± SD) 
= 36.0 ± 2.0 
Weight, kg (mean ± 
SD) = 67.0 ± 3.5 
Walking test: Treadmill protocol; 6 mins of 
walking starting at 1.5 km/h with 0.5 km/h 
increase in speed after 3 mins 
Walking speed: 1.5 km/h, 2.0 km/h 
Gas exchange measurement: Open circuit 
spirometry using rubber balloon, expired gas 
measured using dry gas meter (Singer model 
DTM 115, American Meter Division, USA) 
Calculation method: Net VO2/walking speed 
Walking aids: No aids used 
 
Oxygen cost (ml/kg/m) 
MS: 0.267 ± 0.018 
Controls: 0.162 ± 0.008 
Mean difference (95% CI): -0.105 
(-0.116, -0.094), p < 0.001 





JBI = 7 
N = 12 (F/M NR) 
MS type: 17% RRMS, 
83% SPMS  
EDSS: NR  
Age, years (mean ± SD) 
= 53.0 ± 8.0 
Weight, kg (mean ± 
SD) = 81.8 ± 18.3 
 
N = 12 (F/M NR) 
Age, years (mean ± SD) 
= 52.0 ± 7.3 
Weight, kg (mean ± 
SD) = 69.2 ± 13.6 
Walking test: Overground walking; 5 mins  
Walking speed: Preferred walking speed (mean 
± SD = 0.43 ± 0.15 m/s) 
Gas exchange measurement: COSMED K4b2 
(Cosmed, Italy) 
Calculation method: Gross VO2/walking speed 
Walking aids: 67% unilateral aid, 33% bilateral 
aid 
Oxygen cost (ml/kg/m) 
MS: 0.46 ± 0.16 
Controls: 0.18 ± 0.03 
Mean difference (95% CI): -0.280 








JBI = 8 
N = 46 (27 F/19 M) 
MS type: NR  
EDSS (median (range)): 
3 (1-4) 
Age, years (mean ± SD) 
= 39.0 ± 8.0 
Weight: NR 
 
N = 36 (21 F/ 15M) 
Age, years (mean ± SD) 
= 40.0 ± 9.0 
Weight: NR 
Walking test: Overground walking; 6MWT 
Walking speed: Self-selected walking speed  
(mean ± SD = 1.33 ± 0.25 m/s) 
Gas exchange measurement: Oxycon Mobile 
(Jäger, Germany) 
Calculation method: Gross VO2/walking speed 
Walking aids: No aids used 
Oxygen cost (ml/kg/m) 
MS: 0.219 ± 0.050 
Controls: 0.170 ± 0.030 
Mean difference: -0.049 (-0.068, -
0.030), p < 0.05 





JBI = 8 
N = 18 (14 F/4M) 
MS type: 83% RRMS, 
11% benign MS, 6% 
PPMS  
PDDS (median 
(range)): 1 (0-4)  
Age, years (mean ± SD) 
= 41.9 ± 12.6 
Weight, kg (mean ± 
SD) = 72.1 ± 16.4 
 
N = 18 (14 F/4 M) 
Age, years (mean ± SD) 
= 39.1 ± 11.9 
Weight, kg (mean ± 
SD) = 72.8 ± 15.0 
Walking test: Treadmill walking; three 6-min 
walking trials at a constant speed separated by 
6 mins 
Walking speed: 54 m/min, 80 m/min, 107 
m/min 
Gas exchange measurement: TrueOne (Parvo 
Medics, USA) 
Calculation method: Gross VO2/walking speed 
Walking aids: No aids used 
54 m/min oxygen cost (ml/kg/m) 
MS: 0.202 ± 0.023 
Controls: 0.186 ± 0.010 
Mean difference: -0.016 (-0.028, -
0.004), p < 0.05 
 
80 m/min oxygen cost (ml/kg/m) 
MS: 0.179 ± 0.020 
Controls: 0.163 ± 0.013 
Mean difference: -0.016 (-0.027, -
0.005), p < 0.05 
 
107 m/min oxygen cost (ml/kg/m) 
MS: 0.190 ± 0.024 
Controls: 0.172 ± 0.011 
Mean difference: -0.018 (-0.031, -








JBI = 8 
 
N = 43 (38 F/5 M) 
MS type: 88% RRMS, 
6% SPMS, 6% PPMS  
PDDS (median 
(range)): 1 (0-5) 
Age, years (mean ± SD) 
= 47.2 ± 9.1 
Weight, kg (mean ± 
SD) = 75.7 ± 19.4 
 
N = 43 (38 F/5 M) 
Age, years (mean ± SD) 
= 46.5 ± 10.0 
Weight, kg (mean ± 
SD) = 75.4 ± 16.2 
Walking test: Treadmill walking; five 6-min 
walking trials at a constant speed separated by 
6 mins 
Walking speed: 54 m/min, 67 m/min, 80 
m/min, 94 m/min, 107 m/min 
Gas exchange measurement: TrueOne (Parvo 
Medics, USA) 
Calculation method: Gross VO2/walking speed 
Walking aids: No aids used 
 
54 m/min oxygen cost (ml/kg/m) 
MS: 0.200 ± 0.026 
Controls: 0.187 ± 0.027 
Mean difference: -0.013 (-0.024, -
0.001), p < 0.05 
 
67 m/min oxygen cost (ml/kg/m) 
MS: 0.184 ± 0.025 
Controls: 0.169 ± 0.022 
Mean difference: -0.015 (-0.025, -
0.005), p <0.01 
 
80 m/min oxygen cost (ml/kg/m) 
MS: 0.171 ± 0.019 
Controls: 0.156 ± 0.019 
Mean difference: -0.015 (-0.023, -
0.007), p < 0.01 
 
94 m/min oxygen cost (ml/kg/m) 
MS: 0.167 ± 0.014 
Controls: 0.157 ± 0.021 
Mean difference: -0.010 (-0.018, -
0.002), p < 0.05 
 
107 m/min oxygen cost (ml/kg/m) 
MS: 0.167 ± 0.016 
Controls: 0.162 ± 0.026 
Mean difference: -0.005 (-0.014, 








JBI = 7 
 
N = 10 (9 F/1 M) 
MS type: 90% RRMS, 
10% PPMS  
EDSS (mean ± SD) = 
4.6 ± 1.1 
Age, years (mean ± SD) 
= 45.0 ± 8.0 
Weight, kg (mean ± 
SD) = 74.4 ± 14.0 
 
N = 14 (11 F/3 M) 
Age, years (mean ± SD) 
= 46.0 ± 7.0 
Weight, kg (mean ± 
SD) = 73.4 ± 16.3 
Walking test: Treadmill walking; three 5-min 
walking trials at a constant speed separated by 
5-10 mins 
Walking speed: 0.6 m/s, 1.4 m/s, preferred 
walking speed 
Gas exchange measurement: TrueMax2400 
Metabolic Measurement System (Parvo 
Medics, USA) 
Calculation method: Net VO2/walking speed 
Walking aids: No aids used 
 
0.6 m/s oxygen cost (ml/kg/m) 
MS: 0.25 ± 0.09 
Controls: 0.14 ± 0.06 
Mean difference: -0.110 (-0.173, -
0.047), p ≤ 0.001 
 
1.4 m/s oxygen cost (ml/kg/m) 
MS: 0.11 ± 0.03 
Controls: 0.10 ± 0.03 
Mean difference: -0.010 (-0.036, 
0.016), p > 0.05 
 
Preferred speed oxygen cost 
(ml/kg/m) 
MS: 0.10 ± 0.08 
Controls: 0.06 ± 0.04 
Mean difference: -0.040 (-0.091, 
0.011), p > 0.05 
 
Devasahayam 




JBI = 8 
N = 14 (10 F/4 M) 
MS type: 7% RRMS, 
71% SPMS, 22% PPMS  
EDSS: NR 
Age, years (mean ± SD) 
= 54.1 ± 8.5 
Weight: NR 
N = 7 (4 F/3 M) 
Age, years (mean ± SD) 
= 50.7 ± 12.1 
Weight: NR 
Walking test: Overground walking; 5 mins 
Walking speed: self-selected speed (mean ± SD 
= 0.53 ± 0.32 m/s) 
Gas exchange measurement:  
VmaxST, v1.0 (Sensor Medics, USA) 
Calculation method: Gross VO2/walking speed 
Walking aids: 43% unilateral aid, 43 % 
bilateral aid, 14% unilateral or bilateral aid 
Oxygen cost (ml//kg/m) 
MS: 0.60 ± 0.30 
Controls: 0.22 ± 0.04 
Mean difference: -0.380 (-0.621, -
0.139), p < 0.01 
 
* Values presented as mean  ± SD unless stated otherwise  
Abbreviations: 6MWT, 6-Minute Walk Test; EDSS, Expanded Disability Status Scale; F, Female; JBI, Joanna Briggs Institute Critical Appraisal Checklist for Analytical 
Cross-Sectional Studies; M, Male; MS, Multiple Sclerosis; NR, Not reported; PDDS, Patient Determined Disease Steps; PPMS, Primary Progressive Multiple Sclerosis; 




Table S2 Characteristics and main findings of the studies which investigated the association between oxygen cost of walking and fatigue in 






demographics Oxygen cost of walking measurement 
Fatigue outcome 
measure Main findings 





JBI = 6 
N = 44 (38 F/6 M) 
MS type: 90% RRMS, 5% 
SPMS, 5% PPMS  
PDDS (median (range)): 1 
(0-3) 
Age, years (mean ± SD) = 
47.2 ± 9.1 
Weight, kg (mean ± SD) = 
75.7 ± 19.4 
 
Walking test: Treadmill walking; 6 mins at 
constant speed 
Walking speed: 54 m/min 
Gas exchange measurement: TrueOne (Parvo 
Medics, USA) 
Calculation method: Net VO2/walking speed 
Walking aids: No aids used 
FSS Correlation with FSS:  






JBI = 6 
N = 82 (63 F/19 M) 
MS type: 78% RRMS, 
22% SPMS/PPMS  
PDDS (median (range)): 3 
(0-6) 
Age, years (mean ± SD) = 
49.1 ± 9.0 
Weight, kg (mean ± SD) = 
80.3 ± 21.7 
 
Walking test: Overground walking; 6MWT  
Walking speed: Self-selected walking speed 
(mean ± SD = 0.98 ± 0.33 m/s) 
Gas exchange measurement: COSMED K4b2 
(Cosmed, Italy) 
Calculation method: Net VO2/walking speed 
Walking aids: NR 
FSS Correlation with FSS: 
r = 0.223, p < 0.05 
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Chung et al. 




JBI = 7 
N = 10 (9 F/1 M) 
MS type: 90% RRMS, 
10% PPMS  
EDSS (mean ± SD) = 4.6 
± 1.1 
Age, years (mean ± SD) = 
45.0 ± 8.0 
Weight, kg (mean ± SD) = 
74.4 ± 14.0 
 
Walking test: Treadmill walking; three 5-
minute walking trials at a constant speed 
separated by 5-10 minutes 
Walking speed: 0.6 m/s, 1.4 m/s, preferred 
walking speed 
Gas exchange measurement: TrueMax2400 
Metabolic Measurement System (Parvo 
Medics, USA) 
Calculation method: Net VO2/walking speed 






Correlation with VAS: 
0.6 m/s: r ≤ 0.350, p ≥ 0.1  
1.4 m/s: r ≤ 0.350, p ≥ 0.1 
Preferred speed: r ≤ 0.350, p ≥ 0.1 
Devasahayam 




JBI = 8 
N = 14 (10 F/4 M) 
MS type: 7% RRMS, 71% 
SPMS, 22% PPMS  
EDSS: NR 
Age, years (mean ± SD) = 
54.1 ± 8.5 
Weight: NR 
Walking test: Overground walking; 5 mins 
Walking speed: self-selected speed (mean ± 
SD = 0.53 ± 0.32 m/s) 
Gas exchange measurement:  
VmaxST, v1.0 (Sensor Medics, USA) 
Calculation method: Gross VO2/walking 
speed 
Walking aids: 43% unilateral aid, 43 % 







Correlation with FSS: 
r = -0.432, p > 0.05 
 
Correlation with MFIS: 
r = -0.154, p > 0.05 
 
Correlation with SF-36: 
r = 0.160, p > 0.05 
 
Correlation with change in VAS:  
r = 0.626, p < 0.05  
Abbreviations: 6MWT, 6-Minute Walk Test; EDSS, Expanded Disability Status Scale; F, Female; FSS, Fatigue Severity Scale; JBI, Joanna Briggs Institute Critical 
Appraisal Checklist for Analytical Cross-Sectional Studies; M, Male; MFIS, Modified Fatigue Impact Scale; MS, Multiple Sclerosis; NR, Not reported; PDDS, Patient 
Determined Disease Steps; PPMS, Primary Progressive Multiple Sclerosis; RRMS, Relapsing Remitting Multiple Sclerosis; SF-36 Medical Outcomes Study 36-item Short 





Table S3 Quality assessment using the Joanna Briggs Institute Critical Appraisal Checklist for Analytical Cross-Sectional Studies 
Study 












3. Was the 
exposure 





















7. Were the 
outcomes 







Olgiati et al.19 Y N U Y Y Y Y Y 
Paul et al.20 Y Y U Y Y Y Y Y 
Franceschini et 
al.21 Y Y Y Y Y Y Y Y 
Motl et al.10 Y Y Y Y Y Y Y Y 
Motl et al.13 Y Y Y Y N/A N/A Y Y 
Sandroff et 
al.22 Y Y Y Y Y Y Y Y 
Sandroff et 
al.12 Y Y Y Y N/A N/A Y Y 
Chung et al. 23 Y Y U Y Y Y Y Y 
Devasahayam 
et al. 24 
Y Y Y Y Y Y Y Y 
Abbrevaitions: N, No; N/A, Not applicable U, Unclear; Y, Yes 
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Figure S1 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 
flow diagram  
Records identified through 
database searching September 
2020 (n=282):  
CINAHL (n=60); MEDLINE 
(n=67); ProQuest (n=101); Web 
of Science (n=54) 
Records after duplicates removed 
(n=162) 
Full-text articles assessed for 
eligibility (n=23) 
Articles included in the review; 
(n=9); meta-analysis (n=5) 
Records excluded (n=139) Records screened (n=162) 
Full-text articles excluded (n=14):  
 did not include a control group or 
fatigue outcome measure (n=6) 
 did not include a measure of oxygen 
cost of walking (n=5) 
 did not report the difference in oxygen 
cost of walking between people with 
MS and healthy controls (n=1) 
 did not report the relationship between 
oxygen cost of walking and fatigue 
(n=1) 
 results reported in another article (n=1) 
